Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California 94304, USA.
Kidney Int. 2011 Jan;79(1):14-22. doi: 10.1038/ki.2010.336. Epub 2010 Sep 22.
Cognitive impairment, including dementia, is a common but poorly recognized problem among patients with end-stage renal disease (ESRD), affecting 16-38% of patients. Dementia is associated with high risks of death, dialysis withdrawal, hospitalization, and disability among patients with ESRD; thus, recognizing and effectively managing cognitive impairment may improve clinical care. Dementia screening strategies should take into account patient factors, the time available, the timing of assessments relative to dialysis treatments, and the implications of a positive screen for subsequent management (for example, transplantation). Additional diagnostic testing in patients with cognitive impairment, including neuroimaging, is largely based on the clinical evaluation. There is limited data on the efficacy and safety of pharmacotherapy for dementia in the setting of ESRD; therefore, decisions about the use of these medications should be individualized. Management of behavioral symptoms, evaluation of patient safety, and advance care planning are important components of dementia management. Prevention strategies targeting vascular risk factor modification, and physical and cognitive activity have shown promise in the general population and may be reasonably extrapolated to the ESRD population. Modification of ESRD-associated factors such as anemia and dialysis dose or frequency require further study before they can be recommended for treatment or prevention of cognitive impairment.
认知障碍,包括痴呆,是终末期肾病(ESRD)患者中常见但认识不足的问题,影响 16-38%的患者。痴呆与 ESRD 患者的死亡、透析退出、住院和残疾风险增加有关;因此,识别和有效管理认知障碍可能会改善临床护理。痴呆筛查策略应考虑患者因素、可用时间、评估相对于透析治疗的时间以及阳性筛查对后续管理(例如移植)的影响。在认知障碍患者中,除了临床评估外,还包括神经影像学在内的其他诊断性测试。在 ESRD 背景下,针对痴呆症的药物治疗的疗效和安全性的数据有限;因此,这些药物的使用决策应个体化。行为症状的管理、患者安全性的评估和预先护理计划是痴呆症管理的重要组成部分。针对血管危险因素修改、身体和认知活动的预防策略在普通人群中显示出了希望,并且可以合理地推广到 ESRD 人群。需要进一步研究 ESRD 相关因素(如贫血和透析剂量或频率)的修改,然后才能推荐用于治疗或预防认知障碍。